Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.7195
USD
|
+2.79%
|
|
+6.51%
|
-19.16%
|
Fiscal Period: April |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
94.88
|
53.06
|
4.941
|
-
|
-
|
Enterprise Value (EV)
1 |
94.88
|
53.06
|
4.941
|
4.941
|
4.941
|
P/E ratio
|
-7.29
x
|
-3.65
x
|
-0.42
x
|
-0.5
x
|
-1.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-12
x
|
-4.71
x
|
-0.46
x
|
-0.33
x
|
-
|
EV / FCF
|
-14,118,053
x
|
-5,945,806
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
7.3
x
|
-
|
-1.36
x
|
-0.29
x
|
-
|
Nbr of stocks (in thousands)
|
6,201
|
6,463
|
6,867
|
-
|
-
|
Reference price
2 |
15.30
|
8.209
|
0.7195
|
0.7195
|
0.7195
|
Announcement Date
|
7/19/22
|
7/27/23
|
-
|
-
|
-
|
Fiscal Period: April |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-7.907
|
-11.26
|
-10.7
|
-15.2
|
-
|
EBIT
1 |
-
|
-12.32
|
-14.87
|
-11.8
|
-18.61
|
-26.23
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-12.36
|
-14.88
|
-11.8
|
-18.61
|
-26.23
|
Net income
1 |
-5.047
|
-12.36
|
-14.88
|
-11.8
|
-18.61
|
-26.23
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.050
|
-2.100
|
-2.250
|
-1.730
|
-1.445
|
-0.5600
|
Free Cash Flow
|
-
|
-6.72
|
-8.923
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/29/21
|
7/19/22
|
7/27/23
|
-
|
-
|
-
|
Fiscal Period: April |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-2.304
|
-1.426
|
-2.615
|
-
|
-2.385
|
-3.91
|
-2.808
|
-3.513
|
-2.571
|
-2.461
|
-2.5
|
-3.8
|
-3.8
|
-3.8
|
-3.8
|
EBIT
1 |
-3.584
|
-2.557
|
-3.873
|
-3.036
|
-3.106
|
-5.424
|
-3.305
|
-3.526
|
-2.902
|
-2.66
|
-2.7
|
-4
|
-4
|
-4
|
-4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.6
|
-2.573
|
-3.869
|
-
|
-3.11
|
-5.426
|
-3.306
|
-3.528
|
-2.906
|
-2.662
|
-2.7
|
-4
|
-4
|
-4
|
-4
|
Net income
1 |
-3.6
|
-2.573
|
-3.869
|
-3.037
|
-3.11
|
-5.426
|
-3.306
|
-3.528
|
-2.906
|
-2.662
|
-2.7
|
-4
|
-4
|
-4
|
-4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.4500
|
-0.7500
|
-0.4500
|
-0.4500
|
-0.9000
|
-0.4500
|
-0.6000
|
-0.4400
|
-0.3800
|
-0.3800
|
-0.5500
|
-0.5400
|
-0.5400
|
-0.5300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/13/21
|
3/15/22
|
7/19/22
|
9/13/22
|
12/12/22
|
3/15/23
|
7/27/23
|
9/13/23
|
12/15/23
|
3/25/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: April |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-6.72
|
-8.92
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
2.100
|
-
|
-0.5300
|
-2.520
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.11
|
-
|
0.3
|
0.4
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/29/21
|
7/19/22
|
7/27/23
|
-
|
-
|
-
|
Last Close Price
0.7195
USD Average target price
21
USD Spread / Average Target +2,818.69% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.16% | 4.94M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|